IO Biotech common stock removed from Nasdaq

IO Biotech, Inc. notifies that its Common Stock has been removed from listing and/or registration on the Nasdaq Stock Market LLC under Form 25.

Rhea-AI Filing Summary

IO Biotech, Inc. notifies that its Common Stock has been removed from listing and/or registration on the Nasdaq Stock Market LLC under Form 25.

The filing states Nasdaq followed 17 CFR 240.12d2-2 procedures and that the issuer complied with Exchange rules governing a voluntary withdrawal.

Insights

Corporate Governance Counsel

Nasdaq delisted IO Biotech's common stock via Form 25 after exchange and issuer procedures.

The filing records a procedural removal of the Common Stock from Nasdaq and cites 17 CFR 240.12d2-2 compliance by both the Exchange and the issuer. The action is presented as a voluntary withdrawal under exchange rules.

Timing and post-delisting market arrangements are not stated; subsequent disclosures or exchange notices will be required to explain trading venue changes or investor mechanics.

Key Figures

Commission File Number: 333-260301 Cited Rule: 17 CFR 240.12d2-2 Expires/Date on header: March 31, 2018 +1 more

4 metrics

Commission File Number 333-260301 Form 25 cover

Cited Rule 17 CFR 240.12d2-2 Nasdaq compliance citation

Expires/Date on header March 31, 2018 header expiry line

Issuer phone +45 2194 7856 Issuer principal executive office contact

Key Terms

Form 25, 17 CFR 240.12d2-2, voluntary withdrawal

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

voluntary withdrawal regulatory

"the Issuer has complied with its rules of the Exchange and the requirements governing the voluntary withdrawal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does IO Biotech's Form 25 filing mean for IOBT shareholders?

This Form 25 indicates the issuer's Common Stock was removed from Nasdaq after compliance with 17 CFR 240.12d2-2. The filing describes a voluntary withdrawal and does not state subsequent trading venues or shareholder mechanics; further company notices are needed for details.

Did Nasdaq follow required rules when removing IOBT from the exchange?

Yes. Nasdaq certifies it complied with exchange rules and cites 17 CFR 240.12d2-2. The filing states both the Exchange and the issuer satisfied the procedural requirements for striking the class of securities from listing and/or withdrawing registration.

Does the Form 25 filing state whether the removal was voluntary for IOBT?

The filing states the issuer complied with rules governing the voluntary withdrawal of the class of securities. It explicitly cites the issuer's compliance with Exchange rules and the governing provision, 17 CFR 240.12d-2(c).

Where is IO Biotech headquartered according to the filing?

The filing lists the issuer's principal executive offices at Ole Maaloes Vej 3, Copenhagen, DENMARK 2200 and provides a telephone number of +45 2194 7856. This is the address shown on the Form 25 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 02:01 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-260301

Issuer:	IO Biotech, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	Ole Maaloes Vej 3
	Copenhagen	DENMARK	2200
Telephone number:					+45 2194 7856

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-06-08	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.